Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CVSI NYSEARCA:DBV NASDAQ:ENLV NASDAQ:RLYB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVSICV Sciences$0.03-4.9%$0.04$0.02▼$0.05$6.10M0.65203,574 shs16,316 shsDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AENLVEnlivex Therapeutics$1.06-1.3%$1.24$0.81▼$2.10$24.97M0.83258,787 shs119,759 shsRLYBRallybio$0.59-2.1%$0.53$0.22▼$1.24$24.57M-1.11.13 million shs73,055 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVSICV Sciences0.00%+3.27%-9.64%+28.52%-25.70%DBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%ENLVEnlivex Therapeutics0.00%+0.94%-41.21%+3.88%-31.85%RLYBRallybio0.00%-1.28%-0.53%+70.68%-46.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVSICV Sciences$0.03-4.9%$0.04$0.02▼$0.05$6.10M0.65203,574 shs16,316 shsDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AENLVEnlivex Therapeutics$1.06-1.3%$1.24$0.81▼$2.10$24.97M0.83258,787 shs119,759 shsRLYBRallybio$0.59-2.1%$0.53$0.22▼$1.24$24.57M-1.11.13 million shs73,055 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVSICV Sciences0.00%+3.27%-9.64%+28.52%-25.70%DBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%ENLVEnlivex Therapeutics0.00%+0.94%-41.21%+3.88%-31.85%RLYBRallybio0.00%-1.28%-0.53%+70.68%-46.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVSICV Sciences 0.00N/AN/AN/ADBVInvesco DB G10 Currency Harvest Fund 0.00N/AN/AN/AENLVEnlivex Therapeutics 3.00Buy$10.00846.97% UpsideRLYBRallybio 2.00Hold$5.00750.34% UpsideCurrent Analyst Ratings BreakdownLatest CVSI, DBV, ENLV, and RLYB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.009/2/2025ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/18/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.007/29/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.007/22/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVSICV Sciences$15.70M0.39N/AN/A$0.01 per share3.30DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/ARLYBRallybio$640K38.39N/AN/A$1.49 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVSICV Sciences-$2.39MN/A0.00∞N/A-10.36%-80.82%-19.38%N/ADBVInvesco DB G10 Currency Harvest FundN/AN/A0.00∞N/AN/AN/AN/AN/AENLVEnlivex Therapeutics-$15.01M-$0.58N/AN/AN/AN/A-58.31%-50.32%N/ARLYBRallybio-$57.78M-$0.94N/AN/AN/A-5,473.33%-71.66%-65.06%11/6/2025 (Estimated)Latest CVSI, DBV, ENLV, and RLYB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025RLYBRallybio-$0.2450-$0.22+$0.0250-$0.22N/A$0.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVSICV SciencesN/AN/AN/AN/AN/ADBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVSICV Sciences0.121.040.30DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AENLVEnlivex TherapeuticsN/A6.416.41RLYBRallybioN/A9.989.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVSICV SciencesN/ADBVInvesco DB G10 Currency Harvest Fund85.24%ENLVEnlivex Therapeutics1.02%RLYBRallybio90.34%Insider OwnershipCompanyInsider OwnershipCVSICV Sciences1.30%DBVInvesco DB G10 Currency Harvest FundN/AENLVEnlivex Therapeutics12.28%RLYBRallybio8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVSICV Sciences70184.79 million182.39 millionNot OptionableDBVInvesco DB G10 Currency Harvest Fund801.00 millionN/ANot OptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableRLYBRallybio4041.79 million38.15 millionNot OptionableCVSI, DBV, ENLV, and RLYB HeadlinesRecent News About These CompaniesRallybio receives $12.5M equity milestone payment from Recursion PharmaceuticalsSeptember 3, 2025 | msn.comRallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 ProgramSeptember 3, 2025 | finance.yahoo.comRallybio Granted Extension for Nasdaq ComplianceAugust 29, 2025 | tipranks.comTD Cowen Reaffirms Their Buy Rating on Rallybio (RLYB)August 12, 2025 | theglobeandmail.comRallybio First Half 2025 Earnings: US$0.43 loss per share (vs US$0.83 loss in 1H 2024)August 9, 2025 | finance.yahoo.comRallybio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 8, 2025 | finance.yahoo.comEvercore ISI Remains a Hold on Rallybio (RLYB)July 16, 2025 | theglobeandmail.comRXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia ... - NasdaqJuly 11, 2025 | nasdaq.comRallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - MorningstarJuly 9, 2025 | morningstar.comMHere's Why Shares in Recursion Pharmaceuticals Surged TodayJuly 8, 2025 | finance.yahoo.comRallybio Sells Interest in REV102 Program to Recursion PharmaceuticalsJuly 8, 2025 | finance.yahoo.comRecursion to buy Rallybio’s ownership in jointly developed bone disorder drugJuly 8, 2025 | msn.comRallybio Sells REV102 Program to Recursion PharmaceuticalsJuly 8, 2025 | tipranks.comRallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic StudyJune 13, 2025 | finance.yahoo.comRallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlookMay 24, 2025 | investing.comRallybio shareholders elect directors, ratify auditorMay 18, 2025 | uk.investing.comRallybio Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finance.yahoo.comRallybio to Present at the 2025 Citizens JMP Life Sciences ConferenceApril 29, 2025 | finance.yahoo.comJones Trading Downgrades Rallybio (RLYB)April 15, 2025 | msn.comRallybio downgraded to Hold from Buy at JonesResearchApril 14, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVSI, DBV, ENLV, and RLYB Company DescriptionsCV Sciences OTCMKTS:CVSI$0.03 0.00 (-4.90%) As of 12:39 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.Invesco DB G10 Currency Harvest Fund NYSEARCA:DBV$25.41 0.00 (0.00%) As of 03/10/2023PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.Enlivex Therapeutics NASDAQ:ENLV$1.06 -0.01 (-1.31%) As of 02:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Rallybio NASDAQ:RLYB$0.59 -0.01 (-2.13%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
